How should we use convalescent plasma therapies for the management of COVID-19? | Zendy

Erica M. Wood | Zendy; Lise J Estcourt | Zendy; Zoe McQuilten | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

How should we use convalescent plasma therapies for the management of COVID-19?

Author(s) -

Erica M. Wood,

Lise J Estcourt,

Zoe McQuilten

Publication year - 2020

Publication title -

blood

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.515

H-Index - 465

eISSN - 1528-0020

pISSN - 0006-4971

DOI - 10.1182/blood.2020008903

Subject(s) - convalescent plasma , covid-19 , medicine , antibody , clinical trial , immunology , blood transfusion , intensive care medicine , blood product , virology , surgery , outbreak , disease , infectious disease (medical specialty)

Convalescent plasma (CP) from blood donors with antibodies to severe acute respiratory syndrome coronavirus 2 may benefit patients with COVID-19 by providing immediate passive immunity via transfusion or by being used to manufacture hyperimmune immunoglobulin preparations. Optimal product characteristics (including neutralizing antibody titers), transfusion volume, and administration timing remain to be determined. Preliminary COVID-19 CP safety data are encouraging, but establishing the clinical efficacy of CP requires an ongoing international collaborative effort. Preliminary results from large, high-quality randomized trials have recently started to be reported.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research